| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 04/21/2011 | US20110091499 Treatment of pigs with pcv2 antigent |
| 04/21/2011 | US20110091496 Methods and compositions for the delivery of vaccines to disrupted epithelium |
| 04/21/2011 | US20110091490 Novel vaccine for dog |
| 04/21/2011 | US20110091484 Compositions and methods for preventing or treating a viral infection |
| 04/21/2011 | US20110091481 Biomarkers for predicting response to immunosuppressive therapy |
| 04/21/2011 | US20110091480 Antigen-Binding Proteins Targeting S. Aureus Orf0657n |
| 04/21/2011 | US20110091469 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 04/21/2011 | US20110091465 Polypeptides |
| 04/21/2011 | US20110091463 Dual Variable Domain Immunoglobulins and Uses Thereof |
| 04/21/2011 | US20110091456 Treatment of neurological conditions |
| 04/21/2011 | US20110091450 Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| 04/21/2011 | US20110091445 Modulation of intestinal flora of hiv patients |
| 04/21/2011 | US20110091423 Compositions and methods of use of ritonavir for treating hcv |
| 04/21/2011 | US20110091418 Methods for treating viral infections using polyamine analogs |
| 04/21/2011 | US20110091413 Therapeutic use of interleukin-2 mutants |
| 04/21/2011 | US20110091412 Mutant interleukin-2 (il-2) polypeptides |
| 04/21/2011 | US20110091410 Engineered CXCL12 Alpha Locked Dimer Polypeptide |
| 04/21/2011 | US20110091403 Oligosaccharide aldonic acids and their topical use |
| 04/21/2011 | US20110091385 Substituted aryl piperidinylalkynyladenosines as a2ar agonists |
| 04/21/2011 | US20110091383 Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents |
| 04/21/2011 | US20110091372 Dual Variable Domain Immunoglobulins and Uses Thereof |
| 04/21/2011 | DE202010015644U1 Zusätzliches Heilmittel zur Verbesserung von Herpes Viren Additional remedy to improve herpes viruses |
| 04/21/2011 | DE102009049505A1 Use of antimicrobial agent for preparing antiseptic for use in a disinfection method in which ultrasound is used simultaneously, where the disinfection method is e.g. wound healing, preoperative skin disinfection and surface disinfection |
| 04/21/2011 | DE102009048044A1 Verwendung von Magnolol oder Honokiol als antibakterielle, antimycotische, antiparasitäre oder antivirale Wirkstoffe Use of magnolol and honokiol as antibacterial, antifungal, antiparasitic and antiviral agents |
| 04/21/2011 | CA2813740A1 Recombinant human cc10 protein for treatment of influenza |
| 04/21/2011 | CA2777920A1 Aptamer capable of binding to viral hemorrhagic septicemia virus |
| 04/21/2011 | CA2777816A1 Methods and compositions for novel liquid crystal delivery systems |
| 04/21/2011 | CA2777741A1 Antimicrobial compounds and methods of making and using the same |
| 04/21/2011 | CA2777739A1 Antimicrobial compounds and methods of making and using the same |
| 04/21/2011 | CA2777734A1 Antimicrobial compounds and methods of making and using the same |
| 04/21/2011 | CA2777692A1 Isolation of a virus related to canine parvovirus-2 from a raccoon |
| 04/21/2011 | CA2777664A1 Macrocyclic integrase inhibitors |
| 04/21/2011 | CA2777560A1 Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor |
| 04/21/2011 | CA2777384A1 Combination therapy treatment for viral infections |
| 04/21/2011 | CA2777018A1 Novel method for preparing entecavir and intermediate used therein |
| 04/21/2011 | CA2776868A1 Compositions and methods and uses related thereto |
| 04/21/2011 | CA2776310A1 Pharmaceutical compositions |
| 04/21/2011 | CA2775959A1 Dual variable domain immunoglobulins and uses thereof |
| 04/21/2011 | CA2774250A1 C-linked hydroxamic acid derivatives useful as antibacterial agents |
| 04/21/2011 | CA2767541A1 Inhibitors of filovirus entry into host cells |
| 04/20/2011 | EP2311991A1 S. pneumoniae antigens |
| 04/20/2011 | EP2311990A1 S. pneumoniae antigens |
| 04/20/2011 | EP2311989A1 S. pneumoniae antigens |
| 04/20/2011 | EP2311988A1 S. pneumoniae antigens |
| 04/20/2011 | EP2311987A1 S. pneumoniae antigens |
| 04/20/2011 | EP2311958A2 Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| 04/20/2011 | EP2311956A1 Methods for making APO-2 ligand using divalent metal ions |
| 04/20/2011 | EP2311945A1 Bispecific antibodies substituting for functional proteins |
| 04/20/2011 | EP2311944A1 Polypeptides and polynucleotides from coagulase-negative staphylococci |
| 04/20/2011 | EP2311872A1 Albumin fusion proteins |
| 04/20/2011 | EP2311864A1 Recombinant protein-s composition |
| 04/20/2011 | EP2311818A1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug |
| 04/20/2011 | EP2311807A1 Compounds and composition as protein kinase inhibitors |
| 04/20/2011 | EP2311799A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311798A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311797A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311796A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311532A1 Anti-viral griffithsin compounds, compositions, and methods of use |
| 04/20/2011 | EP2311531A1 Anti-viral griffithsin compounds, compositions, and methods of use |
| 04/20/2011 | EP2311530A2 Mammalian genes involved in infection |
| 04/20/2011 | EP2311488A2 Vaccine composition |
| 04/20/2011 | EP2311466A2 Antimicrobial compounds and methods for their use |
| 04/20/2011 | EP2311457A1 Pharmaceutical compositions for treating infections with drug resistant mycobacteria |
| 04/20/2011 | EP2311456A1 Wound and mucous membrane antiseptic based on bispyridiniumalkanes |
| 04/20/2011 | EP2311452A1 Topical composition comprising n-acetyl glucosamine |
| 04/20/2011 | EP2311451A1 Amino-methyl substituted tetracycline compounds |
| 04/20/2011 | EP2310502A1 Regulated genetic suicide mechanism compositions and methods |
| 04/20/2011 | EP2310405A1 Peptide inhibitors of cd40l signaling and uses therefor |
| 04/20/2011 | EP2310396A1 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors |
| 04/20/2011 | EP2310395A1 9-substituted-b-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
| 04/20/2011 | EP2310393A2 Artemisinin and derivatives thereof as antivirals |
| 04/20/2011 | EP2310390A1 6-(c2-6alkylseleno)purines and methods for treating neural measles viral infection therewith |
| 04/20/2011 | EP2310388A2 Pyridopyrimidine compounds as anti-tubercular agents |
| 04/20/2011 | EP2310095A1 Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors |
| 04/20/2011 | EP2310037A2 Conglutin-gamma as medicament and diet supplement |
| 04/20/2011 | EP2309969A2 Delivery product for topical compositions |
| 04/20/2011 | EP2016081B1 Anti-viral pyrimidine nucleoside derivatives |
| 04/20/2011 | EP1976853B1 Novel compounds and use thereof |
| 04/20/2011 | EP1874312B1 Treatment of hpv induced anogenital intraepithelial neoplasia |
| 04/20/2011 | EP1784200B1 Method and composition for modulation of systemic inflammatory responses syndrome (sirs) |
| 04/20/2011 | EP1781662B1 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same |
| 04/20/2011 | EP1603887B1 Hiv replication inhibiting indane substituted pyrimidines |
| 04/20/2011 | EP1505963B1 Hepatitis c virus inhibitors |
| 04/20/2011 | EP1427826B1 HIV- RT-nef-Gag codon optimised DNA vaccines |
| 04/20/2011 | CN1990470B Phthiobuzonum derivative, its manufacturing process, pharmaceutical combination and uses thereof |
| 04/20/2011 | CN1935131B Pharmaceutical use of 1 beta-hydroxy ilexolic acid for inhibiting hepatitis virus |
| 04/20/2011 | CN1930282B Novel lactic acid bacterium |
| 04/20/2011 | CN1883604B Detection method of compound preparation of red sage root and cape jasmine for treating acute and chronic hepatitis |
| 04/20/2011 | CN1876040B Detection method of pharmaceutical composition for treating hepatitis |
| 04/20/2011 | CN1834095B Nonnucleoside antivirus inhibitor, its preparation method and use |
| 04/20/2011 | CN1830445B Composition of tropane derivatives having therapy use and polymorph thereof |
| 04/20/2011 | CN1698620B Cucurbitacin emulsion capable of filtering out and eliminating bacteria and preparation method thereof |
| 04/20/2011 | CN102026990A Novel inhibitors of hepatitis c virus replication |
| 04/20/2011 | CN102026644A Controlled activation of the reuterin-production machinery of lactobacillus reuteri |
| 04/20/2011 | CN102021184A Antigenic polypeptides |
| 04/20/2011 | CN102021175A Optimized grass carp alpha interferon encoding gene and application thereof |
| 04/20/2011 | CN102021170A Small interfering ribonucleic acid (siRNA) molecule of interfering hepatitis B virus gene and application thereof |
| 04/20/2011 | CN102021162A High-activity bifidobacterium powder and preparation method thereof |
| 04/20/2011 | CN102021147A A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof |
| 04/20/2011 | CN102021146A West nile virus NS1 protein monoclonal antibody, identified B cell epitope thereof and application |